A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b and Self Administered Ribavirin for Patients With Chronic HCV Genotype 2 or 3 and Injection Drug Use
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ACTIVATE
- 10 Jun 2017 Biomarkers information updated
- 15 May 2016 Status changed from active, no longer recruiting to completed.
- 24 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 Sep 2015.